We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Philips' (PHG) Q1 Earnings Down Y/Y on Supply Chain Constraints
Read MoreHide Full Article
Koninklijke Philips N.V. (PHG - Free Report) reported first-quarter 2022 adjusted earnings of €0.15 per share, down 46.4% year over year.
Sales increased 2% on a year-over-year basis to €3.92 billion. Comparable sales (includes adjustments for consolidation charges & currency effects) decreased 4% year over year, primarily due to headwinds caused by global supply chain challenges and consequences of the Respironics field action.
Comparable sales in the Personal Health businesses witnessed high-single-digit increase on a year-over-year basis. This was fully offset by a double-digit decline in the Connected Care businesses and low-single-digit decline in the Diagnosis & Treatment businesses.
Philips’ comparable order intake grew 5% year over year in the reported quarter. Diagnosis & Treatment businesses witnessed high-single-digit growth, while the Connected Care business reported flat comparable order intake.
Sales decreased 3% on a comparable basis in growth geographies. Sales in mature geographies were down 4% year over year on a comparable basis.
Koninklijke Philips N.V. Price, Consensus and EPS Surprise
Philips’ shares were down more than 11% following first-quarter 2022 results. Markedly, Philips’ shares have dropped 17.7% to date compared with the Zacks Medical-Products industry’s decline of 12.7%.
Segmental Update
Diagnosis & Treatment revenues increased 3% from the year-ago quarter to €1.91 billion. Comparable sales declined 2% year over year.
Image-Guided Therapy witnessed high-single-digit growth in the reported quarter. However, Ultrasound and Diagnostic Imaging revenues declined due to supply chain shortages and tough year-over-year comparisons.
Connected Care business revenues declined 14% year over year to €993 million. Comparable sales decreased 21%, primarily due to consequences of the Respironics field action and the impact of supply chain headwinds.
Personal Health sales increased 13% year over year to €838 million. Comparable sales were up 8%, with double-digit growth in Oral Healthcare and Mother & Child Care, while remaining flat in Personal Care.
Other segment sales €176 million, up €100 million on a year-over-year basis.
Operating Details
Gross margin contracted 30 basis points (bps) on a year-over-year basis to 38.6% in the reported quarter.
General & administrative expenses, as percentage of sales, decreased 60 bps on a year-over-year basis to 4%. However, selling expenses increased 140 bps to 27.2%. Research & development expenses also increased 160 bps to 12.6%.
In the reported quarter, procurement cost savings totaled €97 million. In response to the inflationary headwinds, Philips is implementing additional cost-saving measures of €150-200 million for 2022.
Restructuring, acquisition-related and other charges amounted to €350 million compared with €301 million in the year-ago quarter. The reported quarter’s figure includes €65 million for the Respironics field action provision, a €100-million provision related to potential higher execution costs of the field action program and €50 million for running remediation costs in Respironics.
Philips’ adjusted earnings before interest, taxes and amortization (“EBITA”) — the company’s preferred measure of operational performance — were negative €107 million against positive EBITA of €61 million.
Diagnosis & Treatment EBITA margins contracted 280 bps on a year-over-year basis to 5.9%. Connected Care adjusted EBITA margin was 0.4% compared with 12.9% in the year-ago quarter.
Personal Health’s adjusted EBITA margins expanded 130 bps on a year-over-year basis to 15.3%.
Balance Sheet
As of Mar 31, 2022, Philips’ cash and cash equivalents were €1.44 billion and total debt was €7 billion. This compares with cash and cash equivalents of €2.30 billion and total debt of €6.98 billion as of Dec 31, 2021.
Guidance
Philips expects 2022 comparable sales growth between 3% and 5%. First-half sales growth is expected to decline in the mid-single-digit range, while in second-half 2022 it is anticipated to witness high-single-digit growth.
Zacks Rank and Stocks to Consider
Phillips currently has a Zacks Rank #5 (Strong Sell).
Image: Bigstock
Philips' (PHG) Q1 Earnings Down Y/Y on Supply Chain Constraints
Koninklijke Philips N.V. (PHG - Free Report) reported first-quarter 2022 adjusted earnings of €0.15 per share, down 46.4% year over year.
Sales increased 2% on a year-over-year basis to €3.92 billion. Comparable sales (includes adjustments for consolidation charges & currency effects) decreased 4% year over year, primarily due to headwinds caused by global supply chain challenges and consequences of the Respironics field action.
Comparable sales in the Personal Health businesses witnessed high-single-digit increase on a year-over-year basis. This was fully offset by a double-digit decline in the Connected Care businesses and low-single-digit decline in the Diagnosis & Treatment businesses.
Philips’ comparable order intake grew 5% year over year in the reported quarter. Diagnosis & Treatment businesses witnessed high-single-digit growth, while the Connected Care business reported flat comparable order intake.
Sales decreased 3% on a comparable basis in growth geographies. Sales in mature geographies were down 4% year over year on a comparable basis.
Koninklijke Philips N.V. Price, Consensus and EPS Surprise
Koninklijke Philips N.V. price-consensus-eps-surprise-chart | Koninklijke Philips N.V. Quote
Philips’ shares were down more than 11% following first-quarter 2022 results. Markedly, Philips’ shares have dropped 17.7% to date compared with the Zacks Medical-Products industry’s decline of 12.7%.
Segmental Update
Diagnosis & Treatment revenues increased 3% from the year-ago quarter to €1.91 billion. Comparable sales declined 2% year over year.
Image-Guided Therapy witnessed high-single-digit growth in the reported quarter. However, Ultrasound and Diagnostic Imaging revenues declined due to supply chain shortages and tough year-over-year comparisons.
Connected Care business revenues declined 14% year over year to €993 million. Comparable sales decreased 21%, primarily due to consequences of the Respironics field action and the impact of supply chain headwinds.
Personal Health sales increased 13% year over year to €838 million. Comparable sales were up 8%, with double-digit growth in Oral Healthcare and Mother & Child Care, while remaining flat in Personal Care.
Other segment sales €176 million, up €100 million on a year-over-year basis.
Operating Details
Gross margin contracted 30 basis points (bps) on a year-over-year basis to 38.6% in the reported quarter.
General & administrative expenses, as percentage of sales, decreased 60 bps on a year-over-year basis to 4%. However, selling expenses increased 140 bps to 27.2%. Research & development expenses also increased 160 bps to 12.6%.
In the reported quarter, procurement cost savings totaled €97 million. In response to the inflationary headwinds, Philips is implementing additional cost-saving measures of €150-200 million for 2022.
Restructuring, acquisition-related and other charges amounted to €350 million compared with €301 million in the year-ago quarter. The reported quarter’s figure includes €65 million for the Respironics field action provision, a €100-million provision related to potential higher execution costs of the field action program and €50 million for running remediation costs in Respironics.
Philips’ adjusted earnings before interest, taxes and amortization (“EBITA”) — the company’s preferred measure of operational performance — were negative €107 million against positive EBITA of €61 million.
Diagnosis & Treatment EBITA margins contracted 280 bps on a year-over-year basis to 5.9%. Connected Care adjusted EBITA margin was 0.4% compared with 12.9% in the year-ago quarter.
Personal Health’s adjusted EBITA margins expanded 130 bps on a year-over-year basis to 15.3%.
Balance Sheet
As of Mar 31, 2022, Philips’ cash and cash equivalents were €1.44 billion and total debt was €7 billion. This compares with cash and cash equivalents of €2.30 billion and total debt of €6.98 billion as of Dec 31, 2021.
Guidance
Philips expects 2022 comparable sales growth between 3% and 5%. First-half sales growth is expected to decline in the mid-single-digit range, while in second-half 2022 it is anticipated to witness high-single-digit growth.
Zacks Rank and Stocks to Consider
Phillips currently has a Zacks Rank #5 (Strong Sell).
Lantheus Holdings (LNTH - Free Report) , Owens & Minor (OMI - Free Report) and Maravai Life Sciences (MRVI - Free Report) are better-ranked stocks worth considering in the same industry. All the three stocks flaunt a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Lantheus, Owens & Minor and Maravai are expected to report their quarterly results on Apr 29, May 3 and May 5, respectively.
On a year-to-date basis, Lantheus has returned 101.9%. However, shares of Owens & Minor and Maravai are down 8.8% and 21.3%, respectively.